Overview: In this episode, join us as we discuss the use of blood eosinophils as a biomarker in severe asthma and whether there is prognostic value in measuring eosinophil levels.

Episode key references and resource links:

• Bruselle GG, and Koppelman GH. N Engl J Med. 2022;386(2):157–171.
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2023. Available from: https://ginasthma.org/2023-gina-main-report/. Access date [June 2023].
• de Groot JC, et al. ERJ Open Research. 2015;1(1):00024–2015.
• Bousquet J, et al. N Engl J Med. 1990;323(15):1033–1039.
• Yancey SW, et al. J. Allergy Clin Immunol. 2017;140(6):1509–1518.

Guest: Dareen Siri, MD, FAAAAI, FACAAI and Matthew Mintz, MD, FACP

Overview: In this episode, join us as we discuss the risks of elevated eosinophil levels and exacerbations, and the role a specialist can play in the management of severe asthma.

Episode references and resource links:

• Price DB, et al. Lancet Respir Med. 2015;3(11):849–858.
• Dougherty RH and Fahy JV. Clin Exp Allergy. 2008;39(2):193–202.
• Chung LP, et al. Respirology. 2020;25(2):161–172.
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2023. Available from: https://ginasthma.org/2023-gina-main-report/. Access date [June 2023].
• Agusti A, et al. Respir Med. 2021;187:106572.

Guest: Dareen Siri, MD, FAAAAI, FACAAI and Matthew Mintz, MD, FACP

Overview: In this episode, join us as we discuss the importance of blood eosinophil testing for improving diagnosis and phenotyping in severe asthma.

Episode key references and resource links:

• Bruselle GG, and Koppelman GH. N Engl J Med. 2022;386(2):157–171.
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2023. Available from: https://ginasthma.org/2023-gina-main-report/. Access date [June 2023].
• Heaney LG, et al. Chest. 2021;160(3):814–830.
• de Groot JC, et al. ERJ Open Research. 2015;1(1):00024–2015.
• Fitzpatrick AM, et al. J Allergy Clin Immunol Pract. 2020;8(2):452–463

Guest: Dareen Siri, MD, FAAAAI, FACAAI and Matthew Mintz, MD, FACP

This podcast will review the unique pathophysiology in older adults with long-term Type 2 diabetes that underlie requirements for combination insulin therapy.

Please take a few minutes to answer this questionnaire to help us evaluate the impact of this program and plan for future educational programs. Click Here

This podcast reviews the specific considerations in appropriately individualizing care for older adults with T2D by reviewing health status, cognition, frailty and their living situation

Please take a few minutes to answer this questionnaire to help us evaluate the impact of this program and plan for future educational programs. Click Here

This podcast focuses on the exploration of treatment approaches in older patients with Type 2 diabetes who are insulin-requiring through case discussion with a focus on simplicity, minimization of hypoglycemia and importance of simplification/de-intensification utilizing an individualized approach by reviewing psychological, medical, functional and social domains.

Please take a few minutes to answer this questionnaire to help us evaluate the impact of this program and plan for future educational programs. Click Here

The complexity behind recurrent UTI management often leaves both patients and clinicians with questions on the optimal management strategy. Should they be treated as an uncomplicated UTI? Are there special considerations or prevention measures? Are there unforeseen or unknown factors contributing to disease incidence? In this second episode, we take a deep dive into the treatment and management of recurrent UTI and explore the impact that this disease has on patients.

Disclaimers:

1. This presentation is sponsored by GSK. The speakers are GSK paid healthcare providers. The content is intended to support disease state education and is considered nonpromotional.
2. The content and views expressed therein do not necessarily reflect the views, policies, or position of Pri-Med. This program is limited to Health Care Professionals (HCPs) only. GSK complies with all state and federal laws including transparent reporting and disclosure of payments and transfers of value to HCPs.

References:

1. Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2019;202(2):282-289. doi: 10.1097/JU.00000000000002963. 
2. Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am. 2003;17(2):227-241. doi: 10.1016/s0891-5520(03)00005-9
3. Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol 2000; 151:1194.
4. Ikäheimo R, Siitonen A, Heiskanen T, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 1996; 22:91.
5. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103.
6. Markowitz MA, Wood LN, Raz S, Miller LG, Haake DA, Kim JH. Lack of uniformity among United States recommendations for diagnosis and management of acute, uncomplicated cystitis. Int Urogynecol J. 2019;30(7):1187-1194. doi:10.1007/s00192-018-3750-z.
7. Labcorp Report – Antibiotic Resistance in Bladder Infections (2019). https://www.labcorp.com/organizations/data/insights[1]analysis#InsightAnalytics-Antibiotic. Accessed December 1, 2022.
8. Langford BJ, Brown KA, Diong C, et al. The Benefits and Harms of Antibiotic Prophylaxis for Urinary Tract Infection in Older Adults. Clin Infect Dis. 2021;73(3):e782-e791. doi:10.1093/cid/ciab116
9. Harding C, Mossop H, Homer T, et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ. 2022;376:e068229. Published 2022 Mar 9. doi:10.1136/bmj-2021-0068229